The Sensex closed 200.85 points lower, or 0.27 per cent, at 73,828.91, while the Nifty ended down by 73.30 points, or 0.33 ...

The US relies heavily on Indian generic medicines, with nearly half of all generic drugs consumed in the US originating from ...

Seaweed farming also presents a lucrative opportunity for farmers, with potential earnings of up to Rs 13.28 lakh per hectare ...

Welcome to the Cipla Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ...

Discover the Cipla Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent stock.

India still relies largely on imported devices and implants, when it comes to MedTech. This offers us a great opportunity to ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

If drug tariffs don’t work, they could result in higher prices for American patients and increase drug shortages. Testing ...

The life of Cipla, the Indian pharma giant, can broadly be divided into three parts: the first 8 decades of altruistic ...

Technical views on F&O market by Rupak De, Senior Technical Analyst, LKP Securities. De suggests Cipla, KFin Technologies, ...

Tariffs should not influence decisions at Indian drug companies, Cipla's top executive said on Friday, as the industry braces ...

In light of uncertainties surrounding US tariffs on pharmaceuticals, Kotak Institutional Equities noted in a recent report that the most likely scenario (for both companies and investors) is that ...